{"entity":{"id":"nct02945566","kind":"trial","name":"Can we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer?","aka":["STAR-TREC"],"tldr":"A phase 2/3 trial of capecitabine in colorectal cancer, run by University of Birmingham, active but no longer recruiting.","summary":"Can we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer? is a phase 2/3, randomised interventional study registered as NCT02945566 by University of Birmingham, with a registry enrolment figure of 380 participants, started 2017-06-14 and due to reach its primary completion in 2027-08. Interventions recorded: Standard TME surgery; Long course concurrent chemoradiation with capecitabine and radiotherapy; Short course radiotherapy. Conditions listed: Adenocarcinoma of the Rectum. Primary outcome: Phase II (Feasibility study) Primary Outcome: Recruitment Rate; Phase III Primary Outcome: Organ Preservation. Colorectal eligibility wording from the registry: \"* Biopsy proven adenocarcinoma of the rectum\". Sites: Belgium, Denmark, Netherlands, Sweden, United Kingdom. United Kingdom sites listed: 1. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT02945566","url":"https://clinicaltrials.gov/study/NCT02945566"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer"],"sections":[],"technologies":["cytotoxic-chemotherapy","imrt-igrt"],"targets":[],"drugs":["capecitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["UK sites (registry): University of Birmingham (Birmingham)."],"nct":"NCT02945566","phase":"2/3","setting":"STAR-TREC: Can we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer?","sponsor":"University of Birmingham","enrolled":380,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct02945566/","neighbours":{"cancer":[{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}